Safety and efficacy of OVV-01 injection for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced solid tumor (melanoma, head/neck, breast, lung, colon, liver, stomach, bone sarcoma, cervical, or nasopharyngeal cancer) that cannot be surgically removed or has spread
- Failed at least two standard cancer treatments (like chemotherapy, immunotherapy, or targeted drugs)
- At least one measurable tumor visible on imaging that is large enough to inject (some tumors must be over 1 cm)
- Good overall health (ECOG score 0–1) with expected survival of at least 12 weeks and normal blood counts and organ function
- No brain cancer spread, recent radiotherapy to the tumor, or serious heart, infection, or autoimmune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines two drugs—OVV-01 (injected directly into tumors) and AK112 (given by vein)—for advanced solid cancers that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
This trial tests an investigational cell therapy called IOV-5001 for people with advanced solid tumors (lung, breast, colon, or head and neck cancer) that has worsened after standard treatments. The goal is to see if this therapy can help shrink tumors or slow their growth.
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
This trial tests a new intravenous drug called IDOV-SAFE in people with advanced solid tumors that have stopped responding to standard treatments or have no effective standard option. The goal is to see if it is safe and effective.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.